Yu F - Search Results

1

Synthetic and immunological studies on trimeric MUC1 immunodominant motif antigen-based anti-cancer vaccine candidates.

Li M, Yu F, Yao C, Wang PG, Liu Y, Zhao W. Li M, et al. Among authors: yu f. Org Biomol Chem. 2018 Feb 7;16(6):993-999. doi: 10.1039/c7ob02976d. Org Biomol Chem. 2018. PMID: 29345713

2

Fully synthetic self-adjuvanting MUC1-fibroblast stimulating lipopeptide 1 conjugates as potential cancer vaccines.

Liu Y, Zhang W, He Q, Yu F, Song T, Liu T, Zhang Z, Zhou J, Wang PG, Zhao W. Liu Y, et al. Among authors: yu f. Chem Commun (Camb). 2016 Sep 18;52(72):10886-9. doi: 10.1039/c6cc04623a. Epub 2016 Aug 17. Chem Commun (Camb). 2016. PMID: 27530357

3

Potentiating the immune response of MUC1-based antitumor vaccines using a peptide-based nanovector as a promising vaccine adjuvant.

Liu Y, Wang Y, Yu F, Zhang Z, Yang Z, Zhang W, Wang PG, Zhao W. Liu Y, et al. Among authors: yu f. Chem Commun (Camb). 2017 Aug 22;53(68):9486-9489. doi: 10.1039/c7cc04386d. Chem Commun (Camb). 2017. PMID: 28799590

4

Ciliary defects caused by dysregulation of O-GlcNAc modification are associated with diabetic complications.

Yu F, Guo S, Li T, Ran J, Zhao W, Li D, Liu M, Yan X, Yang X, Zhu X, Zhou J. Yu F, et al. Cell Res. 2019 Feb;29(2):171-173. doi: 10.1038/s41422-018-0114-7. Epub 2018 Nov 14. Cell Res. 2019. PMID: 30429527 Free PMC article. No abstract available.

5

Design of a MUC1-based tricomponent vaccine adjuvanted with FSL-1 for cancer immunotherapy.

Li M, Wang Z, Yan B, Yin X, Zhao Y, Yu F, Meng M, Liu Y, Zhao W. Li M, et al. Among authors: yu f. Medchemcomm. 2019 Jul 12;10(12):2073-2077. doi: 10.1039/c9md00254e. eCollection 2019 Dec 1. Medchemcomm. 2019. PMID: 32133105 Free PMC article.

6

O-GlcNAc transferase regulates centriole behavior and intraflagellar transport to promote ciliogenesis.

Yu F, Li T, Sui Y, Chen Q, Yang S, Yang J, Hong R, Li D, Yan X, Zhao W, Zhu X, Zhou J. Yu F, et al. Protein Cell. 2020 Nov;11(11):852-857. doi: 10.1007/s13238-020-00746-2. Protein Cell. 2020. PMID: 32607788 Free PMC article. No abstract available.

7

The Adjuvant of α-Galactosylceramide Presented by Gold Nanoparticles Enhances Antitumor Immune Responses of MUC1 Antigen-Based Tumor Vaccines.

Liu Y, Wang Z, Yu F, Li M, Zhu H, Wang K, Meng M, Zhao W. Liu Y, et al. Among authors: yu f. Int J Nanomedicine. 2021 Jan 14;16:403-420. doi: 10.2147/IJN.S273883. eCollection 2021. Int J Nanomedicine. 2021. PMID: 33469292 Free PMC article.

8

An efficient and safe MUC1-dendritic cell-derived exosome conjugate vaccine elicits potent cellular and humoral immunity and tumor inhibition in vivo.

Zhu H, Wang K, Wang Z, Wang D, Yin X, Liu Y, Yu F, Zhao W. Zhu H, et al. Among authors: yu f. Acta Biomater. 2022 Jan 15;138:491-504. doi: 10.1016/j.actbio.2021.10.041. Epub 2021 Oct 30. Acta Biomater. 2022. PMID: 34757230

9

Not Just Anticoagulation-New and Old Applications of Heparin.

Zang L, Zhu H, Wang K, Liu Y, Yu F, Zhao W. Zang L, et al. Among authors: yu f. Molecules. 2022 Oct 17;27(20):6968. doi: 10.3390/molecules27206968. Molecules. 2022. PMID: 36296562 Free PMC article. Review.

10

Exosomes as CNS Drug Delivery Tools and Their Applications.

Sun K, Zheng X, Jin H, Yu F, Zhao W. Sun K, et al. Among authors: yu f. Pharmaceutics. 2022 Oct 21;14(10):2252. doi: 10.3390/pharmaceutics14102252. Pharmaceutics. 2022. PMID: 36297688 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

9,999 results

Search Page

Filters